Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.

J Clin Oncol. 2020 Apr 1;38(10):1006-1018. doi: 10.1200/JCO.19.00895. Epub 2019 Dec 27.

PMID:
31880950
2.

Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

Yang F, Anekpuritanang T, Press RD.

Mol Diagn Ther. 2020 Feb;24(1):1-13. doi: 10.1007/s40291-019-00443-9.

PMID:
31848884
3.

Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.

Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT.

Leukemia. 2019 Dec 16. doi: 10.1038/s41375-019-0688-1. [Epub ahead of print] No abstract available.

PMID:
31844143
4.

Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.

Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, Fan G, Lim JY, Meyers G, Maziarz RT, Cook RJ.

Am J Hematol. 2019 Aug;94(8):902-912. doi: 10.1002/ajh.25514. Epub 2019 Jun 14.

PMID:
31124175
5.

Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.

Brown JT, Beldorth IJ, Laosinchai-Wolf W, Fahey ME, Jefferson KL, Ruskin AK, Roth JJ, Cai L, Watt CD, Press RD, Yang F, Hedges JB, Andruss BF.

J Mol Diagn. 2019 Jul;21(4):718-733. doi: 10.1016/j.jmoldx.2019.03.002. Epub 2019 Apr 23.

6.

A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE.

Cancer Res. 2018 Dec 15;78(24):6762-6770. doi: 10.1158/0008-5472.CAN-18-1638. Epub 2018 Oct 22.

7.

Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.

Alberti MO, Srivatsan SN, Shao J, McNulty SN, Chang GS, Miller CA, Dunlap JB, Yang F, Press RD, Gao Q, Ding L, Heusel JW, Duncavage EJ, Walter MJ.

Leukemia. 2018 Aug;32(8):1874-1878. doi: 10.1038/s41375-018-0193-y. Epub 2018 Jun 29. No abstract available.

8.

CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.

Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16.

9.

The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care.

Kaul KL, Sabatini LM, Tsongalis GJ, Caliendo AM, Olsen RJ, Ashwood ER, Bale S, Benirschke R, Carlow D, Funke BH, Grody WW, Hayden RT, Hegde M, Lyon E, Murata K, Pessin M, Press RD, Thomson RB.

Acad Pathol. 2017 Jul 16;4:2374289517708309. doi: 10.1177/2374289517708309. eCollection 2017 Jan-Dec.

10.

Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.

Arora R, Press RD.

Leuk Lymphoma. 2017 Jan;58(1):8-16. Epub 2016 Jul 14. Review.

PMID:
27412040
11.

Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists.

Press RD, Eickelberg G, McDonald TJ, Halley J, Long T, Tafe LJ, Weck KE.

Genet Med. 2016 Dec;18(12):1206-1213. doi: 10.1038/gim.2016.34. Epub 2016 Apr 28.

PMID:
27124787
12.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.

13.

Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.

Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, Druker BJ, Dao KH.

Am J Hematol. 2016 Feb;91(2):211-9. doi: 10.1002/ajh.24245.

14.

The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients.

Hakki M, Rattray RM, Press RD.

J Clin Virol. 2015 Jul;68:1-5. doi: 10.1016/j.jcv.2015.04.012. Epub 2015 Apr 15.

15.

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW.

Leuk Res Rep. 2014 Aug 1;3(2):67-9. doi: 10.1016/j.lrr.2014.07.002. eCollection 2014.

16.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

17.

Clinical implementation of next-generation sequencing.

Press RD.

Clin Adv Hematol Oncol. 2014 Apr;12(4):263-5. No abstract available.

PMID:
25003357
18.

BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.

Luu MH, Press RD.

Expert Rev Mol Diagn. 2013 Sep;13(7):749-62. doi: 10.1586/14737159.2013.835573. Review.

PMID:
24063401
19.

BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.

Press RD, Kamel-Reid S, Ang D.

J Mol Diagn. 2013 Sep;15(5):565-76. doi: 10.1016/j.jmoldx.2013.04.007. Epub 2013 Jun 27. Review.

20.

Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.

Moore FR, Yang F, Press RD.

Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.

PMID:
23666688

Supplemental Content

Loading ...
Support Center